Onkológia 5/2014

Transplantation of hematopoietic stem cell for myelodysplastic syndrome

Myelodysplastic syndrome (MDS) is a heterogeneous group of chronic myeloid neoplasias, the origin of which begins in the hematopoietic bone marrow stem cells. MDS affects over 80% of patients older than 60 years, that complicates hematopoietic stem cell transplantation application. Moreover, nowadays improved supportive care and nontransplant treatment with intention to prolong survival. However, the introduction of reduced conditioning regimen before hematopoietic stem cell transplantation and unrelated voluntary donors provide the posibility to offer this potentially curatiove therapy to a greater group of patients and to older patients.

Keywords: myelodysplastic syndrome, hematopoietic stem cell transplantation, reduced conditioning